Drug Profile
Research programme: peptide-based vaccines - Pfizer/PYC Therapeutics
Latest Information Update: 15 Sep 2023
Price :
$50
*
At a glance
- Originator Pfizer; Phylogica
- Developer Pfizer; PYC Therapeutics
- Class Peptides; Vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in Australia
- 20 Dec 2010 Early research in Australia (unspecified route)